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Abstract. Earlier work from our laboratory demon- 
strated that heparin inhibited the proliferation of vas- 
cular smooth muscle cells in vivo and in vitro. Both 
anticoagulant and non-anticoagulant heparin species 
were equally effective as antiproliferative agents. Pre- 
vious structure-function studies indicated that hexa- 
saccharide and larger fragments retained antiprolifera- 
tive activity, whereas tetra- and disaccharides were in- 
active. These experiments also suggested that both N- 
and O-sulfates of heparin were necessary for growth 
inhibitory capacity. In this paper, we have further 
analyzed the structural determinants of the antipro- 
liferative activity of heparin. These experiments were 
done using synthetically prepared and therefore chem- 
ically defined heparin oligosaccharides. We present 
evidence that a pentasaccharide fragment retains anti- 
proliferative activity, and that the 3-O-sulfate on the 
internal glucosamine residue is critical for growth in- 
hibitory capacity of the pentasaccharide.  We also 
show that heparins obtained from different manufac- 
turers differ significantly in their ability to suppress 
smooth muscle cell proliferation. 
T 
HE  proliferation  of  vascular  smooth  muscle  cells 
(SMC) ~  after endothelial  injury is thought to be a key 
step in the pathogenesis of arteriosclerosis (Ross and 
Glomset,  1973). Although  much attention has been focused 
on factors that stimulate  SMC proliferation  (Schwartz et al., 
1982), very little is known about the mechanisms involved in 
maintaining  these cells in a quiescent growth state in healthy 
blood vessels, and in re-establishing the quiescent growth state 
of SMC after their proliferative response to intimal injury. 
Earlier work from our laboratory demonstrated that hepa- 
rin  inhibited  the proliferation  of SMC in vivo and in vitro 
(Clowes and Karnovsky,  1977; Guyton et al.,  1980; Hoover 
et al.,  1980; Castellot  et al.,  1981). Both anticoagulant  and 
non-anticoagulant  heparin  species were equally  effective as 
SMC antiproliferative  agents. These studies suggested both a 
pharmacological basis for the use ofhepafin after vessel injury, 
and a possible physiological role for heparin-like  species as 
regulators of SMC growth in the vasculature. 
Previous structure-function studies (Castellot et al., 1984) 
indicated  that hexasaccharide  and larger fragments retained 
antiproliferative  activity,  whereas  tetra-  and  disaccharides 
were inactive  against SMC growth.  These experiments  also 
indicated  that both the N- and  O-sulfates of heparin  were 
necessary for antiproliferative activity, although the N-sulfates 
could be replaced with acetyl groups without significant loss 
1. Abbreviations usedin thispaper: FCS, fetal ealfserum; SMC, smooth muscle 
cells. 
of activity.  Both  the hexasaccharide  fragment  and  the  N- 
desulfated, re-N-acetylated heparin  are devoid of anticoagu- 
lant  activity (Kazatchkine  et al., 1981; Oosta et al., 1981), 
thus providing a chemical basis for the difference between the 
antiproliferative  and anticoagulant  activities of this glycosa- 
minoglycan. 
In this paper, we have further analyzed the structural deter- 
minants  of the antiproliferative  effect of heparin.  These ex- 
periments were done using synthetically prepared and there- 
fore chemically defined heparin oligosaccharides. We present 
evidence that a pentasaccharide fragment retains antiprolifer- 
ative activity, and that the 3-O-sulfate on the internal  gluco- 
samine residue is critical for antiproliferative  capacity of the 
pentasaccharide,  We also show that heparins obtained from 
different manufacturers  differ significantly in their ability to 
inhibit SMC growth. 
Materials and Methods 
Cell Culture 
All cells were cultured at 37°C in a humidified, 5% CO2/95%  air atmosphere. 
All growth media contained 4 mM glut,amine,  100 #g/ml penicillin,  and 100 
gg/ml streptomycin. 
Smooth Muscle Cells 
Rat aortic SMC from Sprague-Dawley  rats (CD strain, Charles River Breeding 
Laboratories,  Inc., Wilmington, MA) were isolated, cultured, and characterized 
as previously described (Hoover et al.,  1980; Castellot et al.,  1982). Briefly, the 
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under a  dissecting microscope.  The aorta was cut longitudinally  and small 
pieces of media were carefully stripped from the vessel wall. Two or three such 
strips were placed in 60-ram tissue culture dishes. Within 1-2 wk, SMC migrate 
from the explants; they were capable of being subedtured about a week al~er 
the first appearance  of cells. They were grown in RPMI-1640  medium that 
contained 20% fetal calf serum (FCS). 
Rat mesenteric artery SMC were isolated by enzymatic digestion as described 
by l.arson et al. (1984). Briefly, the mesenteric artery was removed from Sprague 
Dawley rats and subjected to collagenase and elastase digestion for 25-30 rain 
at 37°C. They were grown in RPMI medium that contained 20% FCS. 
Calf aortic SMC were isolated from explants of bovine aortas as described 
by Ross (1971). They were grown in Dulbecco's modified Eagle's medium that 
contained  10% calf serum. 
Cebus monkey aortic SMC were the generous gift of Dr. Richard  Hoover 
(Harvard Medical School). They were obtained  from primate aortas using the 
explant  method of Ross (1971).  They  were grown  in RPMI  medium that 
contained 20% FCS. 
All smooth muscle cell types were identified as SMC by the presence of (a) 
numerous myofilament  bundles in the cytoplasm, (b) numerous vesicles near 
the plasma membrane, (c) SMC-speeific myosin,  as revealed by indirect im- 
munofluorescence  (Larson  et al., 1984), and (d) characteristic  "hiUoeks and 
valleys" appearance of confluent cultures. 
Growth-arrest of Cells 
To growth-arrest  SMC, sparsely plated  cultures  were washed and placed  in 
RPMI  +  2%  platelet-poor  plasma or in RPMI +  0.4% FCS for 72 h. Flow 
microfluorimetry indicated that -90% of the cells were arrested in Go(G0. 
Inhibition Assay 
To assay for the antiproliferative  activity  of hepatin,  5-8  x  103  SMC were 
plated into 16-ram multiwell plates in normal growth medium. After 24 h, they 
were growth arrested as described above. Control  cultures were released from 
Go by placing them in RPMI +  20%  FCS. Other cultures were exposed to 
RPMI  +  20%  FCS that contained  heparin.  Cell numbers were measured  in 
duplicate samples using a Coulter counter. Trypsinized cultures were routinely 
checked by direct microscopic examination  to ascertain that the trypsinization 
procedure had not lysed the cells and to ensure that all cells were removed from 
the multiwell. The cells were not fed during the experiment. The net growth of 
SMC in control cultures was obtained  by subtracting the starting cell number 
(at the time the cells are released from Go) from the cell number at the end of 
the experiment.  The net growth  of SMC in heparin-containing  medium is 
computed in a similar fashion. The degree of inhibition is determined from the 
following relationship 
net growth in heparin~ 
Percent inhibition  =  1 -  net growth ~n~) ×  100. 
Preparation of Heparin Oligosaccharides 
The synthesis and chemical  characterization  of the heparin  derivatives and 
their effects on coagulation factors have been described elsewhere in great detail 
(Sache et al., 1982; Choay et al.,  1983; Sinay et al.,  1984; Petitou,  1984). The 
chemical structure  of some of these fragments is shown in Fig. 1; the letters 
that designate the fragments and the residues are based on the nomenclature 
used  in the above-mentioned  reports.  In addition  to the synthetic  heparins 
shown in Fig. 1, we also tested a higher molecular weight (7,000-11,000  D; this 
fraction  still shows some polydispersity) non-anticoagulant  heparin  obtained 
by ion exchange chromatography,  and two lower molecular  weight heparin 
species (2,500 and 4,500 D), prepared  by controlled depolymerization  which 
have  no  activity  against  thrombin (Factor  IIa) but have  high  Factor  Xa- 
inhibiting  activity. These two compounds are considered antithrombotic  but 
have low anticoagulant  activity. 
Results 
Antiproliferative Activity of a 
Heparin Pentasaccharide 
In our previous structure-function studies, we had found that 
hexasaccharide fragments of heparin were moderately active, 
while tetra- and disaccharide species  were totally inactive. 
These heparin fragments were prepared by nitrous acid cleav- 
age followed by gel fdtration ofheparin. This procedure yields 
heparin fragments with even numbers of sugar residues, if we 
include the reducing end 2,5-anhydromannose; thus we could 
not determine the antiproliferative activity of a pentasaccha- 
ride species. The recent chemical synthesis of a pentasaccha- 
ride heparin fragment of known structure (Fig. 1, fragment a; 
Choay et al.,  1983)  made it possible  to directly assay the 
activity of this  oligosaccharide (Fig.  2).  When  SMC  from 
several species and from two different types of arteries were 
exposed to pentasaccharide a, their growth was inhibited by 
an average of 46% at 100 ttg/ml, 31% at 10 #g/ml, and 17% 
at 1 gg/ml. This is approximately the same degree of inhibi- 
tion seen when these cells were treated with the hexasaccha- 
ride fragment.  The activity of some  of the  larger heparin 
fragments as well as the lack of effect of smaller species is also 
shown for comparison. 
We considered the possibility that the reason for the inac- 
tivity  of the  tetrasaccharide  species  in  our  earlier  studies 
(Castellot et al.,  1984) was  that the method of preparation 
yielded a mixture of different tetrasaccharide fragments (in- 
cluding, as mentioned above, the 2,5-anhydromannose resi- 
due at the reducing end) rather than a single pure tetrasaccha- 
ride of  known structure, and that other specific tetrasaccharide 
structures might possess  some antiproliferative activity. To 
test this possibility,  we synthesized the two tetrasaccharides 
shown in Fig. 1, one (fragment c) that lacked the nonreducing 
terminus residue of pentasaccharide a,  and the  other that 
lacked the terminal residue from the reducing end (fragment 
d). When these compounds were assayed for their antipro- 
liferative activity (Fig. 3), they inhibited SMC growth by 18- 
22% at 100 ~g/ml. In terms of potency, the tetrasaccharides 
were 20-100 times less active than pentasaccharide a. This is 
slightly more antiproliferative than the tetrasaccharide mix- 
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Figure 1. Chemical structure of some of the heparin derivatives  used 
in this communication. 
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Figure 2. Effect of a chemically synthesized heparin pentasaccharide 
(a) on the proliferation of several SMC types. SMC from the rat aorta 
(A), Cebus monkey aorta (B), rat mesenteric artery (C), and calf  aorta 
(D) were growth-arrested as described in Materials and Methods. 
These cultures were released from the Go block by placing them in 
RPMI + 20% FCS with or without the indicated concentrations of 
heparin or heparin derivatives. Cell number was determined after 5- 
7 d, at which time growth in both control and heparin-treated cultures 
had  ceased. The commercial  heparin  used  was  from  Laboratoire 
Choay, and had a molecular weight of ~ 15,000 (40-50 residues), m, 
dodecasaccharide fragment; @, commercial heparin; O, decasacchar- 
ide; #, octasaccharide; rq, hexasaccharide; &, pentasaccharide a; A, 
tetrasaccharide; O, disaccharide. 
ture  produced  by  gel  filtration, but  still  substantially less 
activity than pentasaccharide a (Fig. 3). From the above data, 
we conclude that tetrasaccharide heparin fragments have a 
negligible  capacity to inhibit SMC growth, while pentasaccha- 
ride a and larger species retain this ability. 
Evidence for a Critical O-Sulfate in 
the Pentasaccharide 
To determine if a particular structural feature was critical for 
maintaining the antiproliferative activity of pentasaccharide 
a, we synthesized (Choay et al., 1983) a novel pentasaccharide 
(Fig.  1, fragment b), which did not contain a  3-O-sulfate on 
residue F (the internal glucosamine), The resulting molecule 
could inhibit SMC proliferation by only 23%  at  100 ~g/ml 
(Fig. 4). In terms of potency, pentasaccharide b was ~20-fold 
less active than pentasaccharide a,  which contained a  3-0- 
sulfate on residue F. These data suggest that the 3-O-sulfate 
on residue F is critical for conferring growth inhibitory activ- 
ity. 
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Figure 3. Effect of tetrasaccharides on SMC growth. Rat mesenteric 
artery SMC were growth-arrested and then exposed to RPMI + 20% 
FCS with or without the indicated heparin derivatives for 5-7 d, at 
which time cell number was determined. Tetrasaccharide c lacks the 
terminal sugar at the nonreducing end of pentasaccharide a. Tetra- 
saccharide d lacks the terminal residue from the reducing end of 
pentasaccharide  a.  A  mixture  of tetrasaccharides obtained  by gel 
filtration (Oosta et al., 1981) was also tested. Virtually identical results 
were obtained when these heparin species were assayed on rat aortic 
and calf aortic SMC. 
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Figure 4. Role of the 3-O-sulfate on the internal  glucosamine residue. 
A pentasaccharide lacking the 3-O-sulfate on the internal (F) gluco- 
samine residue was synthesized (pentasaccharide b) and tested for its 
ability to  inhibit the  proliferation  of rat  mesenteric  artery  SMC. 
Essentially identical results were obtained using rat and calf aortic 
SMC. 
Antiproliferative Activity of  Non-anticoagulant 
Heparin Species 
We had previously found that heparin, which was devoid of 
anticoagulant activity by virtue of its failure to bind to  an 
Castellot et al. Structure-Function  Relationships  of  Heparin  1981 antithrombin  III affinity column, was as potent and effica- 
cious an antiproliferative agent as highly anticoagulant ma- 
terial  (Castellot et al.,  1981).  Heparin  inhibits a  number of 
procoagulant proteases mainly by binding to antithrombin III 
and enhancing the effects of this inhibitor.  With respect to 
this inhibition, the blood coagulation proteases may be clas- 
sifted into two types: Factor Xa type and Factor IIa (thrombin) 
type. Heparin would be defined as anticoagulant if it has high 
6C 
20 
activity against thrombin. Some heparin species may have no 
activity against Factor IIa but have high Xa-inhibiting activity, 
and could be considered antithrombotic but non-anticoagu- 
lant.  As the activity against thrombin derives from beparin 
binding to antithrombin  III, this provides the rationale  for 
the use of antithrombin III affinity column chromatography 
to produce non-anticoagulant heparin. 
Two heparin fragments with low anticoagulant activity were 
0  1  10  t00 
HEPA RIN (/.tg/ml) 
prepared and tested for their ability to inhibit SMC growth 
(Fig.  5):  (a) a  4,500-D product derived from the controlled 
depolymerization of commercial heparin,  and (b) a 2,500-D 
product  also  derived  from  controlled  depolymerization  of 
commercial heparin. These products have significant activity 
against Factor Xa (Yin et al.,  1973) but almost no activity 
against Factor IIa (Larsen et al.,  1978),  and are antithrom- 
botic. These were compared to a  7,000-11,000-D non-anti- 
coagulant,  non-antithrombotic heparin prepared by ion ex- 
change chromatography (Sache et al.,  1982).  All of these low 
anticoagulant heparins possess substantially the same antipro- 
liferative activity as anticoagulant species (Fig. 5). 
Antiproliferative  Capacity of  Heparins from 
Different Sources 
We  had  noted empirically that heparin  from some sources 
yielded more consistent inhibition of SMC growth than oth- 
ers,  especially  at  the  lower doses.  We  therefore  tested  the 
ability of heparins obtained from ten different manufacturers 
to inhibit rat aortic SMC proliferation (Fig. 6). All the heparins 
Figure  5. Effect of non-anticoagulant  heparins on SMC proliferation. 
Rat aortic SMC were exposed to non-anticoagulant  heparin species 
which were prepared  in different ways and which differed in their 
abilities  to  accelerate  the  inhibition  of Factors  IIa and  Xa  (see 
Materials  and Methods  for references). The 7,000-11,000-D  non- 
anticoagulant heparin (O) was prepared by ion exchange chromatog- 
raphy.  The 4,500- (&) and 2,500-D  species (A) were prepared  by 
controlled depolymerization  and by extraction  and fractionation  of 
native  heparin,  respectively. Both of these compounds have  little 
activity against thrombin (Factor IIa) and high activity against Factor 
Xa, and are thus considered antithrombotic  but low anticoagulant. 
Similar results were obtained with rat mesenteric artery, calf aortic, 
and Cebus monkey aortic SMC. O, commercial heparin. 
100 
tested were effective at  100 ttg/ml, although Choay, Elkins- 
Sinn, and Upjohn heparins were somewhat more efficacious. 
At  l0 t,g/ml,  the  difference between these  three producers 
and  the others  was more pronounced.  At  1 ttg/ml,  a  wide 
spread between the various sources was observed, with some 
heparins actually stimulating SMC growth slightly at this dose. 
Discussion 
In this paper, we have investigated some of the precise struc- 
tural determinants  of the ability of heparin to inhibit SMC 
proliferation.  The basis for these studies is a series of obser- 
,  1 pg/ml  10 pg/ml  ,  lOOpg/ml 
iiiiiil  iiil  iiii  ~  iiiiiil 
6O 
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Figure 6.  Effect of heparins  ob- 
tained  from  different  sources. 
Commercial  grade  heparins  were 
obtained  from ten  suppliers  and 
assayed for their ability to inhibit 
the growth of rat aortic SMC. Es- 
sentially the same results were ob- 
tained using rat mesenteric artery 
SMC. The  asterisks (*)  indicate 
that the Lilly and Riker  heparins 
stimulated SMC growth slightly at 
the  1 #g/ml dose  (12  and  19%, 
respectively). 
The Journal of Cell Biology,  Volume 102, 1986  1982 vations made in our laboratory over the past several years, 
which demonstrate that heparin inhibited the growth of SMC 
in vivo and in vitro (Clowes and Karuovsky, 1977; Guyton 
et al.,  1980; Hoover et al.,  1980; Castellot et at.,  1981). In our 
previous structure-function studies (Castellot et al.,  1984), we 
used heparin fragments and chemically modified commercial 
heparin to determine that the smallest antiproliferative frag- 
ment was a hexasaccharide, and that both N- and O-sulfates 
were important for maintaining the growth inhibitory capac- 
ity of heparin. Several of the heparin fragments and modifi- 
cations which retained antiproliferafive activity had lost their 
anticoagulant activity, in particular the hexa- to dodecasac- 
charide species, and the N-desulfated, re-N-acetylated deriv- 
ative.  On  the basis  of these studies,  we  hypothesized that 
antiproliferative, non-anticoagulant heparin species might be 
clinically useful after vascular procedures that produce injury 
to the vessel wall. These would include vein grafts, angioplas- 
ties, arteriovenous shunts (for kidney dialysis), and endarter- 
ectomies. A significant number of these procedures, perhaps 
as high as 20%, appear to fail because of SMC hyperplasia 
(Whittemore et al.,  1981). 
The above structure-function experiments were done with 
compounds derived from commercial heparin, a very heter- 
ogeneous mixture of heparin glycosaminoglycans. The recent 
chemical synthesis of heparin oligosaccharides by Choay and 
co-workers (Choay et al.,  1983; Sinay et al.,  1984; Petitou, 
1984) has allowed a more critical examination of the precise 
molecular determinants of the antiproliferative capacity. A 
pentasaccharide (Fig.  l, fragment a) was found to have ap- 
proximately the same growth inhibitory effect as hexasaccha- 
rides.  When a pentasaccharide (Fig.  l, fragment b) was syn- 
thesized which did not have the 3-O-sulfate moiety on the F 
residue, it was 20 times less potent than the pentasaccharide, 
which  contained the  3-O-sulfate.  We conclude from these 
data that a critical structure for antiproliferative heparin is a 
pentasaccharide fragment with  a  3-O-sulfate group on  the 
internal glucosamine residue. This conclusion is further sup- 
ported by the inability of the two synthetic tetrasaccharide 
fragments (Fig. 1, c and d) to inhibit SMC growth, since these 
fragments also contain the 3-O-sulfate moiety and have the 
same charge density as pentasaccharide a. Our data do not 
rule out the possibility that other fragments with O-sulfate 
groups not in position 3, or in position 3 on residues other 
than F, can be active. The answer to this question awaits the 
chemical synthesis and bioassay of new heparin pentasaccha- 
ride fragments. It should be noted that the criticality of 3-0- 
sulfate groups in larger heparin fragments has not yet been 
established. Indeed, our studies indicate that higher molecular 
weight,  low-affinity heparins,  which  do  not  contain  3-0- 
sulfate groups, are antiproliferative, which suggests that the 
active structure does not depend solely on the presence of the 
3-O-sulfate group. It is also worth mentioning that the obser- 
vation that pure, synthetic heparin fragments are antiprolifer- 
ative makes it highly unlikely that the antiproliferative effect 
that we and others observe with native preparations is due to 
a contaminant in these heterogeneous mixtures. 
Two other aspects of the antiproliferative nature of  heparin 
were examined. First, heparins that were rendered low or non- 
anticoagulant were tested and found to possess antiprolifera- 
tive  activity.  Neither of the  low  anticoagulant  derivatives 
retained the capacity to inhibit Factor IIa (thrombin). We 
therefore may conclude that the anticoagulant and antipro- 
liferative properties are clearly separate. It is unlikely that the 
growth inhibitory effect of heparin is mediated by kallikrein, 
since the ability of heparin to inhibit this protease depends 
upon the heparin-antithrombin III interaction (Bun'owes et 
al.,  1975; Vennerod and Laake, 1975). Since these tow anti- 
coagulant species have very low Xa-inhibitory activity, these 
data  also  rule out the  possibility that the  antiproliferative 
activity could be due to the interaction of heparin with Factor 
Xa or a similar type of enzyme. 
The second aspect we considered was the confusing varia- 
bility in the capacity of heparin to inhibit SMC growth in our 
laboratory as well as other laboratories. We had noticed that 
heparin  from  certain  sources was  more potent and  more 
consistent than heparin from other suppliers.  We obtained 
heparin from ten different producers and found that consid- 
erable  differences existed between  them,  especially at  the 
lower doses. The reasons for this are unclear, but it is apparent 
that to obtain the most consistent antiproliferative effect one 
must use heparin from Laboratoire Choay, Elkins-Sinn, or 
Up  john. 
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